Table 2.

HERV-K expression in melanoma cell lines and in melanoma biopsies

PatientHERV-K expressionMelanoma marker expressionClinical data
FL *envrecMIAMART-1Age SexTumor thickness (mm)Stage Type (c/l)
1BA+++++++41f4IIIc
LAU+++++++52mn.d.IIIc
SCHM+++++++55f2IVc
SCHW+++++++42f4IVc
TR++++++69fn.d.IVl
ZO+++++++64f2.55IIIc
AC+++++n.d.++69fn.d.IVc
2AD++/−n.d.+55fn.d.IIIl
3KU+++++61m5IVc
RA+++++84f3.7IVc
SO+++++59m5IVl
ZD+++++55m5IVc
AB+n.d.++68m1.1IVc
AF+n.d.+/−39m1IVn.d.
AG+n.d.++80f0.64IVc
AI+n.d.+/−47mn.d.IVl
AJ+n.d.+46m10IVc
AK+n.d.+/−63m5IVl
4MA §+59fn.d.n.d.n.d.
5FE+++++++80fn.d.IIIl
FM+++++++28fn.d.IVLung
KLM++++++++++50mn.d.IIIl
MA+++++++58fn.d.IVl
SC+++++++64mn.d.IIIl
TB+++++++58fn.d.IVl
HI+++++++67fn.d.IVBrain
AA++++n.d.++62mn.d.IVl
AB+++/−+/−n.d.++68mn.d.IVc
AC++++/−n.d.++69wn.d.IVc
AH+++++n.d.++44wn.d.IVc
6LU++/−++++69fn.d.IIIc
SE+++++86fn.d.IVc
AF+++n.d.++39mn.d.IVn.d.
AG++n.d.++80wn.d.IVc
7BN++++44mn.d.IIIl
GB++++/−42fn.d.IVLung
HK+++++42fn.d.IVc
KH+++++64fn.d.IIIc
LA+++++44mn.d.IVc
LAN+++++65mn.d.IIIl
LG+++++75mn.d.IIIl
OL++++41mn.d.n.d.n.d.
PV+++++81fn.d.IIIc
SR+++++60mn.d.n.d.l
VH+++++81mn.d.n.d.l
WD++++59mn.d.IVl
WR++++72mn.d.IVc
AD++n.d.++55wn.d.IIIl
AE++n.d.++56wn.d.IVc
AI++n.d.++47mn.d.IVl
AJ++n.d.++46mn.d.IVc
AK++n.d.++63mn.d.IVl
8LH ++71fn.d.n.d.n.d.
  • NOTE: Patient groups 1, 2, and 3: melanoma cell lines; patient groups 5, 6, and 7: melanoma biopsies; ++, strong expression; +, expression; +/−, weak expression; −, no expression. Abbreviations: n.d., not determined; c, cutaneous; l, lymph node metastases.

  • * Full-length mRNA.

  • Age at first tumor diagnosis.

  • American Joint Committee on Cancer 2001: stage III—lymph node or cutaneous metastases between primary tumor and regional lymph node; stage IV—distant metastases.

  • § Breast carcinoma.

  • Merkel cell carcinoma.